Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Cash from Financing Activities of -$11.4 million for Q1 2026, down 2750.0% year-over-year from $430188.7 in Q1 2025, and up 89.99% quarter-over-quarter from -$113.9 million in Q4 2025.
Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 2750.0% year-over-year to -$11.4 million; the TTM figure through Mar 2026 stood at -$147.6 million (up 36.13% YoY), while the FY2025 annual figure was -$136.6 million, up 28.11% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$11.4 million, up from -$113.9 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $353.1 million in Q4 2022, with the low at -$486.9 million in Q2 2023.
- The 5-year median for Cash from Financing Activities is -$11.4 million (2026), against an average of -$23.1 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 4686.0% in 2022, then tumbled 22880.0% in 2025.
- Emergent BioSolutions' Cash from Financing Activities stood at $353.1 million in 2022, then slumped by 98.67% to $4.7 million in 2023, then slumped by 89.36% to $500000.0 in 2024, then sank by 22880.0% to -$113.9 million in 2025, then soared by 89.99% to -$11.4 million in 2026.
- Business Quant data shows EBS's Cash from Financing Activities at -$11.4 million in Q1 2026, -$113.9 million in Q4 2025, and -$15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -24.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.40 Mn |
| Jun 30, 2026 | -24.40 Mn |
| Mar 31, 2026 | -11.40 Mn |
| Mar 31, 2026 | -11.40 Mn |
| Dec 31, 2025 | -113.90 Mn |
| Dec 31, 2025 | -113.90 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -400,000.00 |
| Mar 31, 2025 | -400,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | -180.30 Mn |
| Sep 30, 2024 | -180.30 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | 40.70 Mn |
| Mar 31, 2024 | 40.70 Mn |